These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 12034371)

  • 21. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
    Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
    J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.
    Ghosh AK; Gemma S; Takayama J; Baldridge A; Leshchenko-Yashchuk S; Miller HB; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
    Org Biomol Chem; 2008 Oct; 6(20):3703-13. PubMed ID: 18843400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural study of ribonucleotide reductase inhibitor hydrazones. Synthesis and X-ray diffraction analysis of a copper(II)-benzoylpyridine-2-quinolinyl hydrazone complex.
    Tamasi G; Chiasserini L; Savini L; Sega A; Cini R
    J Inorg Biochem; 2005 Jun; 99(6):1347-59. PubMed ID: 15869799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
    Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design.
    Wlodawer A; Vondrasek J
    Annu Rev Biophys Biomol Struct; 1998; 27():249-84. PubMed ID: 9646869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy.
    Kempf DJ; Sham HL; Marsh KC; Flentge CA; Betebenner D; Green BE; McDonald E; Vasavanonda S; Saldivar A; Wideburg NE; Kati WM; Ruiz L; Zhao C; Fino L; Patterson J; Molla A; Plattner JJ; Norbeck DW
    J Med Chem; 1998 Feb; 41(4):602-17. PubMed ID: 9484509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.
    Perryman AL; Lin JH; Andrew McCammon J
    Chem Biol Drug Des; 2006 May; 67(5):336-45. PubMed ID: 16784458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamics of "flap" structures in three HIV-1 protease/inhibitor complexes probed by total chemical synthesis and pulse-EPR spectroscopy.
    Torbeev VY; Raghuraman H; Mandal K; Senapati S; Perozo E; Kent SB
    J Am Chem Soc; 2009 Jan; 131(3):884-5. PubMed ID: 19117390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rational design of inhibitors for drug-resistant HIV-1 aspartic protease mutants.
    Frecer V; Miertus S; Tossi A; Romeo D
    Drug Des Discov; 1998 Oct; 15(4):211-31. PubMed ID: 10546067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, crystal structure, and cytotoxic activity of novel cyclic systems in [1,2,4]thiadiazolo[2,3-a]pyridine benzamide derivatives and their copper(II) complexes.
    Adhami F; Safavi M; Ehsani M; Ardestani SK; Emmerling F; Simyari F
    Dalton Trans; 2014 Jun; 43(21):7945-57. PubMed ID: 24715093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting dynamic pockets of HIV-1 protease by structure-based computational screening for allosteric inhibitors.
    Kunze J; Todoroff N; Schneider P; Rodrigues T; Geppert T; Reisen F; Schreuder H; Saas J; Hessler G; Baringhaus KH; Schneider G
    J Chem Inf Model; 2014 Mar; 54(3):987-91. PubMed ID: 24528206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.
    Dewdney TG; Wang Y; Liu Z; Sharma SK; Reiter SJ; Brunzelle JS; Kovari IA; Woster PM; Kovari LC
    Bioorg Med Chem; 2013 Dec; 21(23):7430-4. PubMed ID: 24128815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis, characterization, cellular uptake and interaction with native DNA of a bis(pyridyl)-1,2,4-oxadiazole copper(II) complex.
    Terenzi A; Barone G; Piccionello AP; Giorgi G; Guarcello A; Portanova P; Calvaruso G; Buscemi S; Vivona N; Pace A
    Dalton Trans; 2010 Oct; 39(38):9140-5. PubMed ID: 20820603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir.
    Klei HE; Kish K; Lin PF; Guo Q; Friborg J; Rose RE; Zhang Y; Goldfarb V; Langley DR; Wittekind M; Sheriff S
    J Virol; 2007 Sep; 81(17):9525-35. PubMed ID: 17537865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.
    Sham HL; Zhao C; Stewart KD; Betebenner DA; Lin S; Park CH; Kong XP; Rosenbrook W; Herrin T; Madigan D; Vasavanonda S; Lyons N; Molla A; Saldivar A; Marsh KC; McDonald E; Wideburg NE; Denissen JF; Robins T; Kempf DJ; Plattner JJ; Norbeck DW
    J Med Chem; 1996 Jan; 39(2):392-7. PubMed ID: 8558507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.
    Logsdon BC; Vickrey JF; Martin P; Proteasa G; Koepke JI; Terlecky SR; Wawrzak Z; Winters MA; Merigan TC; Kovari LC
    J Virol; 2004 Mar; 78(6):3123-32. PubMed ID: 14990731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Copper(I)-dioxygen reactivity of [(L)Cu(I)](+) (L = tris(2-pyridylmethyl)amine): kinetic/thermodynamic and spectroscopic studies concerning the formation of Cu-O2 and Cu2-O2 adducts as a function of solvent medium and 4-pyridyl ligand substituent variations.
    Zhang CX; Kaderli S; Costas M; Kim EI; Neuhold YM; Karlin KD; Zuberbühler AD
    Inorg Chem; 2003 Mar; 42(6):1807-24. PubMed ID: 12639113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linear and cyclic glycopeptide as HIV protease inhibitors.
    Pawar SA; Jabgunde AM; Maguire GE; Kruger HG; Sayed Y; Soliman ME; Dhavale DD; Govender T
    Eur J Med Chem; 2013 Feb; 60():144-54. PubMed ID: 23291117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and DNA binding studies of Ni(II), Co(II), Cu(II) and Zn(II) metal complexes of N1,N5-bis[pyridine-2-methylene]-thiocarbohydrazone Schiff-base ligand.
    Tiwari AD; Mishra AK; Mishra SB; Mamba BB; Maji B; Bhattacharya S
    Spectrochim Acta A Mol Biomol Spectrosc; 2011 Sep; 79(5):1050-6. PubMed ID: 21570900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.